The management team is exploring potential non-dilutive funding sources, including milestone payments from existing collaborations with Bristol-Myers Squibb (NYSE: BMY) and Beam Therapeutics, as ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab, which achieved significant ...

The company already has collaborations with Bristol-Myers Squibb and Beam Therapeutics, which could provide milestone payments to extend the cash runway. These existing relationships demonstrate the ...

Prime Medicine also maintains its cystic fibrosis program, which is supported by the Cystic Fibrosis Foundation, and collaborates with Bristol Myers Squibb to develop Prime Edited CAR-T products ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Looking into the current session, Bristol-Myers Squibb Inc. BMY shares are trading at $47.05, after a 1.22% drop. Over the ...

Discover why Bristol-Myers Squibb's undervalued stock, strong cash flow, and 5% dividend yield make it an attractive buy ...

Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

Bristol Myers Squibb to cut 68 jobs in Lawrenceville as part of a broader restructuring effort aiming to slash $2B in costs ...

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...